Year: 2017
Type: article
Abstract: Current trends in auditory rehabilitation for single-sided deafness (SSD) reflect a renewed interest in the functional impact of unilateral hearing loss and also in advances in technologies for SSD that make interventions more effective and more appealing to patients. Clinicians are now equipped with an array of therapeutic options ranging from Bluetooth contralateral routing of signal (CROS) devices to in-the-ear bone conduction hearing aids (TransEar, Ear Technology Corp., Johnson City, TE), as well as bone-anchored technologies (BAHA) (Ponto, Oticon Medical AB, Askim, Sweden; Sophono, Medtronic, Dublin 2, Ireland; and BoneBridge, Med-El, South Yorkshire, UK). Even unilateral cochlear implantation represents an emerging (and as of yet, investigational) intervention that may offer yet another option to patients in the future. A persistent deficiency in this field is the absence of concise and evidence-based guidelines for patient and intervention selection. Factors to consider when recommending the best treatment include functional handicapping due to SSD, speech understanding in noise, sound localization, ease of use, the need for surgery, and cost. Imaging compatibility of implantable devices has also posed a potential problem in considering management options. However, the increasing compatibility of current devices with magnetic resonance imaging (MRI) has mitigated this concern. This article seeks to review the pertinent literature on this topic and offer a best-practice framework. Both bone-anchored technologies (BAT) and CROS devices enable patients to access sound from the deaf side, thus effectively expanding the sound field. Some patients are bothered by the CROS device's need for an appliance in their better hearing ear, whereas some reject BATs because of the need for surgery. In a recent systematic review of bone conduction devices and CROS sound systems published by Peters et al.,1 the data continue to suggest that no high-level evidence demonstrates a significant benefit of either intervention in terms of speech perception in noise or sound localization. However, both strategies did provide subjective improvement in speech communication.1 The TransEar (Ear Technology Corp.) hearing aid offers a nonsurgical bone-conduction hearing aid option that can be inserted in the algorithm in addition to BAT and CROS devices for some patients. The TransEar (Ear Technology Corp.) allows transmission of sound by means of an in-the-ear hearing component that contacts the bony portion of the auditory canal. To date, there remains a paucity of data about its use in the literature, and audiologic familiarity/expertise is required to make this an effective hearing rehabilitative option. A prospective pilot study conducted in Europe by Hol et al.2 had 10 subjects with SSD use all three devices: the Baha Soft Band (Cochlear Bone-Anchored Solutions, Mölnlycke, Sweden), a CROS device, and a device that is placed completely in the canal (CIC) in a random order for an 8-week trial period each. The localization was poor across the board, but the results on quality-of-life issues were mixed, with some surprising benefits with the CIC device. At the end of trying all three devices, only three of 10 of the patients chose to proceed with BAHA implantation, and one of 10 chose a CROS device. The authors emphasized that all patients derived some form of benefit for each device, but there is a real need for a sufficient trial period for patients before making an informed decision. Complications and long-term satisfaction with the BAHA need to be considered before committing to a surgery. The Sophono device (Medtronic) was the first to employ a magnetically coupled bone-conduction device that is implanted underneath the skin without any percutaneous abutment. This approach not only eliminates the cosmetic concerns that patients have with an abutment but also the need for a meticulous cleaning of the abutment site and associated wound issues.3 An analogously magnetically coupled bone conduction device (Baha Attract Band, Cochlear Bone-Anchored Solutions)) has since been introduced, along with a novel bone conduction device employing an internal floating mass transducer that is positioned in the mastoid or retromastoid area (Bonebridge, Med-El).4 Preliminary data on the first 12 patients with this new device (and 6 months follow-up) are very limited. Initially, MRI was contraindicated for patients with magnetic implants. However, the Sophono Alpha 2 implant (Medtronic) is MR-compatible with 3 tesla systems and the Baha Attract (Cochlear Bone-Anchored Solutions) with 1.5T imaging. Accordingly, the imaging constraints with these devices are significantly mitigated. Finally, pilot data are also emerging on the potential value of cochlear implantation in single-sided deafness. Friedmann et al describe their experience with 12 adult and four pediatric patients implanted for unilateral severe-to-profound hearing loss. The early data appear to show significant improvements in consonant-vowel nucleus-consonant (CNC) and sentence in noise scores (principally among the adult patients). The data are more scattered among the pediatric implant recipients and do not have sufficient long-term follow-up.5 At this point, further studies are clearly indicated to determine the appropriate patient selection and likely benefits offered by cochlear implantation in single-sided deafness. As a best practice, it is reasonable to consider a sequential interventional approach for SSD patients that takes into consideration the degree of invasiveness or risk associated with each intervention. For example, an initial trial of a CROS or TransEar (Ear Technology Corp.)-type hearing aid can be recommended as a nominal risk, noninvasive option for patients with SSD. If those trials prove unsatisfactory, the patient might then be considered an appropriate candidate for an implantable bone conduction device (e.g., BAHA; Ponto, Oticon Medical AB; or Sophono, Medtronic). Cochlear implantation remains an investigational intervention for patients with handicapping single-sided deafness. One study involved a prospective trial with small sample size, thus qualifying for level II evidence. One included citation provided a systematic review of multiple cohort studies qualifying as level II evidence. Three other studies cited in this Best Practice reported on cohorts of patients studied retrospectively, thus classifying as level IV. The article is an update of “Optimal Management of Single-Sided Deafness,” which was originally published in The Laryngoscope on January 11, 2013. DOI: 10.1002/lary.23483.
Source: The Laryngoscope
DOI: 10.1002/lary.26553
Authors: Christine Heubi, Daniel Choo
Language: English
Subfield: Speech and Hearing
Field: Health Professions
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2596996799
